Genomic DNA in CD34+ hematopoietic stem and progenitor cells (gDNA)

Genomic DNA in CD34+ hematopoietic stem and progenitor cells (HSPCs) serves as the fundamental genetic blueprint for the production of all blood cell types, including red blood cells, white blood cells, and platelets (Source: NIH, 2023). In the field of regenerative medicine, this DNA is the primary substrate for ex vivo gene therapy and gene editing interventions aimed at curing monogenic hematologic disorders (Source: FDA, 2023). By targeting specific loci within the HSPC genome, such as the BCL11A erythroid enhancer or the HBB gene, therapeutic platforms like CRISPR/Cas9 or lentiviral vectors can permanently modify the genetic output of the hematopoietic system (Source: NEJM, 2021). These modified cells are then autologously transplanted back into the patient, where they engraft in the bone marrow to provide a long-term source of functional blood cells. The therapeutic success of targeting this DNA depends on high editing efficiency and the maintenance of stem cell multipotency, while safety concerns focus on avoiding off-target genomic alterations or insertional mutagenesis that could lead to malignancy (Source: Nature, 2023).

Other names

Nuclear DNAChromosomal DNAHSPC genomeHematopoietic stem cell DNA

Therapeutic drugs target this molecule through ex vivo gene addition via lentiviral vectors or precise gene editing using CRISPR/Cas9 to correct or compensate for genetic mutations.